Health & MedicineBreaking NewsBreakingLatest News
FDA Warns of Rare Blindness Risk Linked to Ozempic, Wegovy, and Mounjaro
Sentiment: NeutralHigh Priority
What Happened?
The FDA has raised concerns about a potential risk of rare eye damage associated with Ozempic, Wegovy, and Mounjaro, which could lead to sudden vision loss. Patients are advised to consult healthcare professionals if they experience symptoms.
Key points
- The FDA has flagged a potential risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) linked to GLP-1 medications.
- NAION can cause sudden, painless vision loss, typically affecting one eye.
- Symptoms include blurred vision, blind spots, and changes in color perception.
- The FDA reviewed data from over 134,000 participants and identified 15 probable NAION cases.
- Patients should not stop taking their medications without consulting a doctor.
Key insights
- The FDA's warning may lead to increased scrutiny of GLP-1 medications among healthcare providers.
- Patients with existing risk factors for NAION may need closer monitoring while on these medications.
- The findings could impact the prescribing practices for diabetes and obesity treatments.
Why it matters
This warning highlights the need for ongoing safety monitoring of widely used diabetes and weight-loss medications.
Source
Times Now
